These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-003796-37 Effekt af melatonin på forekomsten af postoperativ træthed og søvnforstyrrelser efter laparoskopisk kolecystektomi. En randomiseret dobbelt-blindet placebo kontrolleret undersøgelse. not-yet-due
Not reported 2005-001248-22 A prospective randomized multicentre study to compare Crinone 8% once daily versus other vaginal progesterone. 2010-01-07 due-trials
Ongoing 2005-004180-28 Kan en enkelt dosis steroid nedsætte mængeden af serom efter mastektomi? et randomiseret pilotstudie not-yet-due
Not reported 2006-001961-40 Phase II study of therapy with Cetuximab and Irinotecan every second week to Irinotecan resistant patients with metastatic colorectal cancer-effect and biological markers 2011-05-27 due-trials
Not reported Terminated 2007-002713-39 Quality of life related to recombinant TSH treatment compared to no treatment related to iodine uptake, in patient with thyroid cancer. A double blinded, randomized crossover study. Dathyrca I 2012-01-01 due-trials
Listed as ongoing, but also has a completion date 2007-005306-49 A phase II study of Vorinostat in patients with Polycythaemia Vera and Essential Thrombocythaemia 2012-08-15 bad-data
Ongoing 2007-007335-99 A Phase II Study of Erlotinib in Patients with Polycythaemia Vera and Essential Thrombocythemia not-yet-due
Completed, but no date Terminated 2007-007596-16 Evaluering af p53-pulset dendritiske celler i kombination med aromatase inhibitor som behandling til brystkræft-patienter med recidiv / progression efter adjuverende eller 1. linje endokrin behandling... bad-data
Completed, but no date 2007-007652-34 Kan mineraltilskud med bismuth mindske toksiciteten af kemoterapi og strålebehandling? En klinisk prospektiv, dobbeltblind randomiseret undersøgelse af patienter med hæmatologiske sygdomme som modtage... bad-data
Completed, but no date 2008-007951-29 Et fase II forsøg af neoadjuverende behandling med pegyleret liposomal doxorubicin (Caelyx®) og cyklofosfamid +/- trastuzumab med efterfølgende docetaxel til patienter med primær inoperabel og lokoreg... bad-data
Not reported 2008-008692-33 Evaluation of cytotoxicity and genetic changes of high dose vitamin C infusions in castration resistant metastatic human prostate cancer. 2014-09-03 due-trials
Not reported 2009-009926-94 Use of combined measurements of serum infliximab and anti-infliximab antibodies in the treatment of patients with Crohns disease failing infliximab therapy 2012-04-04 due-trials
Reported results 2009-010976-94 behandling af patienter med avanceret rectumcancer med capecitabin og oxaliplatin før under og efter kurativt intenderet strålebehandling, samt tillæg af cetuximab til patienter der er K-RAS vild-type 2017-01-11 due-trials
Completed, but no date Terminated 2009-011455-51 Palliative treatment of ulcerated cutaneous metastases: Randomised trial between electrochemotherapy and radiotherapy bad-data
Not reported Terminated 2009-012445-35 Aldosterone receptor blockade in patients with chronic kidney disease. Influence on arterial stiffness and kidney function. 2012-01-27 due-trials
Reported results 2009-014821-17 Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®) in pati... 2017-05-01 due-trials
Reported results 2009-014863-37 Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tu,our in combination with trastuzumab (Herceptin (R)) in p... 2017-05-01 due-trials
Not reported 2009-015952-11 Phase Fase II examination of irinotecan, cetuximab and everolimus for patients resistente to chemoptherapy with metastatic colorectal cancer and KRAS mutation or with KRAS wildtype after progression o... 2011-06-24 due-trials
Not reported 2009-016650-40 Kan injektion af Methylprednisolonacetat (Depo-Medrol) 80 mg i mastektomikaviteten ved drænfjernelsen efter operation for primær mammakancer virke profylaktisk mod seromdannelse ? 2013-05-08 due-trials
Not reported 2009-017736-41 "Fibrinogen-koncentrat som initial behandling ved postpartum blødning" 2013-05-29 due-trials
Not reported 2010-020041-27 Liothyronin (T3) og hjertesvigt 2013-10-14 due-trials
Not reported Terminated 2010-022460-12 The effect of melatonin on depression, anxiety, cogntive function and sleep disturbances in breast cancer patients 2012-12-10 due-trials
Completed, but no date Terminated 2011-000273-31 Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours bad-data
Not reported 2011-001602-10 Dendritic cell vaccination in combination with Docetaxel for patients with prostata cancer - a randomized phase II trial 2016-02-11 due-trials
Not reported Terminated 2011-004577-91 Kombination af IDO og Survivin peptidvaccine med Temozolamid kemoterapi til patienter med metastatisk malignt melanom. 2015-06-05 due-trials
Ongoing 2012-002702-51 Discontinuation of infliximab therapy in patients with Crohn’s disease during sustained complete remission: not-yet-due
Exempt 2012-004350-29 Variations in plasma concentration in patients with non-small cell lung cancer on fixed-dose erlotinib 2015-01-01 not-yet-due
Not reported 2013-000205-23 The analgesic effects of melatonin: A randomized, placebo-controlled, double-blinded study on healthy volunteers 2014-10-08 due-trials
Ongoing 2013-000494-67 Needle fasciotomi vs collagenase for treatment of Dupuytrens contracture in 2nd, 3rd, 4th and 5th metacarpophalangeal joint. not-yet-due
Ongoing 2013-000629-30 The sun protective effect of melatonin: a randomized, placebo-controlled, double-blinded study on healthy volunteers. not-yet-due
Reported results 2013-001559-11 Chemotherapy with gemcitabine, capecitabine, irinotecan and bevacizumab to patients with cholangiocarcinoma after progression on first line treatment. 2017-03-01 due-trials
Not reported 2013-002428-17 Nurse Administered Propofol Sedation vs combined sedation with midazolam/fentanil for colonoscopy in patients with IBD. A randomised controlled trial of satisfaction and adhearence to treatment progra... 2015-09-25 due-trials
Completed, but no date 2013-003023-10 MELATOX: Pharmacodynamic evaluation of topical use of melatonin as sun protection: a randomized, double blinded, placebo controlled crossover study on healthy volunteers. bad-data
Not reported 2013-004854-46 Randomized 1. Line treatment with gemcitabine, capecitabine, oxaliplatin vs gemcitabin and cisplatin to patients with cholangiocarcinoma. 2019-05-01 due-trials
Not reported Terminated 2014-001163-12 A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Gemcitabine (GEM) and Capecitabine (CAP) with or without T-ChOSTM as adjuvant therapy in patients with surgically resecte... 2018-07-03 due-trials
Reported results 2014-001419-38 T-cell therapy in combination with vemurafenib for BRAF mutated metastatic melanoma 2018-12-31 due-trials
Completed, but no date, and reported results Terminated 2014-001420-29 T cell therapy in combination with peginterferon for metastatic malignant melanoma bad-data
Ongoing 2014-003789-25 The anxiolytic and analgesic effects of melatonin: A randomized, placebo-controlled, double-blinded clinical study. not-yet-due
Reported results 2015-000530-30 T cell therapy for patients with advanced Ovarian Cancer 2017-04-03 due-trials
Not reported 2015-001108-76 "AnAnkle Trial": Peripheral nerve block vs. spinal anaesthesia for ankle fracture surgery – implications on pain profile and quality of recovery 2017-05-31 due-trials
Reported results 2015-002519-14 The MIRAD study - Mineralocorticoid Receptor Antagonists in Type 2 Diabetes. A randomised, double-blind, placebo-controlled study of the effect of Mineralocorticoid Receptor Antagonists in Type 2 Diab... 2017-11-10 due-trials
Ongoing 2015-003399-58 Target-ABC (Targetted AntiBiotics for COPD): not-yet-due
Not reported Terminated 2015-004494-33 Anti-IL-17, a possible new treatment for contact dermatitis? 2017-04-25 due-trials
Completed, but no date 2015-005682-24 REDUCING THE IMPACT OF OVARIAN STIMULATION - THE RIOT PROJECT bad-data
Not reported 2015-005683-41 REDUCING THE IMPACT OF OVARIAN STIMULATION - THE RIOT PROJECT 2018-01-09 due-trials
Completed, but no date, and reported results 2015-005772-16 The safety and pharmacokinetics of intraperitoneal administration of granulocyte-macrophage colony-stimulating factor, fosfomycin, and metronidazole in patients undergoing appendectomy for uncomplicat... bad-data
Ongoing 2016-000643-13 A MULTINATIONAL, RANDOMIZED, PHASE II STUDY OF THE COMBINATION OF NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT IL-6R INHIBITOR, TOCILIZUMAB, AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED... not-yet-due
Reported results 2016-000896-26 Effect of Tadalafil on cerebral large arteries in stroke patients. 2017-08-04 due-trials
Ongoing 2016-001219-18 Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in ischemic stroke patients not-yet-due
Not reported 2016-001221-14 Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on 2017-02-02 due-trials
Reported results 2016-001365-92 Meal-time Administration of exenatide for Glycaemic control in type 1 diabetic Cases: A randomised, placebo-controlled trial 2019-06-19 due-trials
Ongoing 2016-001454-18 T cell therapy for patients with advanced Renal Cell Carcinoma not-yet-due
Ongoing 2016-001883-12 A PROSPECTIVE RANDOMIZED, OPEN-LABEL PHASE 2 STUDY OF IMMUNE CHECKPOINT INHIBITION, NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN COMBINATION WITH RADIATION THERAPY IN PRETREATED PATIENTS WITH METASTATIC PA... not-yet-due
Reported results Terminated 2016-002222-37 A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer. 2018-02-08 due-trials
Ongoing 2016-002255-25 Electrochemotherapy versus standard radiatiotherapy for the treatment of basal cell carcinoma not-yet-due
Reported results 2016-003018-29 Apremilast as anti-pruritic treatment in patients with prurigo nodularis 2019-02-27 due-trials
Completed, but no date 2016-003743-10 Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at high cardiovascular risk: The SIMPle Randomized Clinical Trial bad-data
Exempt 2016-004527-23 Combination therapy with Nivolumab and PD-L1/IDO peptide vaccine with Montanide to patients with metastatic malignant melanoma not-yet-due
Exempt 2017-000997-13 Pharmacokinetics of intravenous, rectal, intravesical, vaginal, and transdermal administration of exogenous melatonin in healthy female volunteers: a crossover study 2019-02-21 not-yet-due
Completed, reported early Terminated 2017-002179-24 T-cell therapy in combination with checkpoint inhibitors for patients with advanced ovarian-, fallopian tube- and primary peritoneal cancer. 2020-06-01 not-yet-due
Ongoing 2017-002323-25 Adoptive cell therapy across cancer diagnoses not-yet-due
Reported results 2017-004753-16 Intraperitoneal administration of fosfomycin, metronidazole and molgramostim versus intravenous conventional antibiotics for perforated appendicitis – a pivotal quasi-randomized controlled trial 2018-07-17 due-trials
Ongoing 2018-000097-30 Efficacy of brodalumab in patients with psoriasis with failure of other anti-IL-17 treatments not-yet-due
Ongoing 2018-000726-63 Pre- and Postoperative Imaging and Monitoring of Patients with Primary Hyperparathyroidism: not-yet-due
Ongoing 2018-000875-34 Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids not-yet-due
Ongoing 2018-001705-91 MELADERM-trial: Melatonin cream against acute radiation dermatitis in patients with early breast cancer: a pivotal phase 2, double-blind, randomized, placebo-controlled trial not-yet-due
Ongoing 2018-002595-41 CHECKPOINT INHIBITOR INDUCED COLITIS AND ARTHRITIS – not-yet-due
Completed, report not yet due 2018-002605-62 Phase IIa trial with PD-L1 IO103 vaccination with montanide in patients with basal cell carcinoma. 2020-05-20 not-yet-due
Ongoing 2018-003461-34 Randomised phase 2 trial of stereotactic body radiation therapy, SBRT of a soft tissue metastasis in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer not-yet-due
Ongoing 2018-003990-93 Phase IIa trial of PD-L1 peptide vaccination as monotherapy in high risk smoldering multiple myeloma not-yet-due
Ongoing 2018-004826-27 A Single Center, Randomized, Phase II Study of the combination of Cisplatin and Gemcitabine with or without Tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced o... not-yet-due
Ongoing 2018-004869-14 Peptide vaccination with PD-L1 and PD-L2 peptides in untreated chronic lymphatic leukemia. not-yet-due
Ongoing 2019-000239-21 Characterization of L-T4 treated patients with persistent hypothyroid symptoms - Effect of Synthetic LT4/L-T3 combination therapy versus desiccated animal thyroid extract? not-yet-due
Ongoing 2019-001316-38 A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma not-yet-due
Exempt 2019-001972-12 A phase 1b/2 open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors and advanced breast cancer not-yet-due
Exempt 2019-003759-13 Phase 1/2 study in locally advanced pancreatic cancer to assess safety and potential efficacy of dual checkpoint inhibition in combination with gemcitabine and nab-paclitaxel followed by immune-chemor... not-yet-due
Ongoing 2019-004397-26 FOLFOX + Immunotherapy with intrahepatic administration of oxaliplatin for patients with multiple non-resectable liver metastasis from colorectal cancer. not-yet-due
Ongoing 2019-004438-40 Phase 2 study in pretreated patients with advanced pancreatic cancer to assess efficacy of ipilimumab, nivolumab and tocilizumab in combination with radiation. not-yet-due